Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
7 Biotech Stocks to Boost Your Portfolio to Peak Health
While innovations such as artificial intelligence have become all the rage, there's another type of technology – biotechnology – that deserves careful consideration for your portfolio. Indeed, if y...
AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
Data from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy before and after bladder removal surgery improves survival in patients.
China approves AstraZeneca's Tagrisso-chemo combo as first-line treatment
China has approved the use of AstraZeneca's blockbuster cancer drug Tagrisso in combination with chemotherapy as a first line of treatment for adults with a type of advanced lung cancer, the compan...
AstraZeneca disappointed with failure of immunotherapy in early-stage lung cancer
AstraZeneca PLC (LSE:AZN) shared some disappointing news on an advanced lung cancer trial of its Imfinzi immunotherapy. Phase III trials showed the drug did not achieve statistical significance for...
BenevolentAI says second target identified by AstraZeneca collaboration
BenevolentAI (OTC:BAIVF) said that AstraZeneca PLC (LSE:AZN) has identified a target for systemic lupus erythematosus (SLE) using the former's artificial intelligence-driven drug discovery platform...
AstraZeneca says Imfinzi fails in late-stage trial to treat type of lung cancer
AstraZeneca said on Tuesday its blockbuster cancer drug, Imfinzi, failed to improve disease-free survival in a late-stage trial to treat a type of early-stage lung cancer.
3 No-Brainer Stocks to Buy for Under $100 Right Now
AstraZeneca should have lots of growth ahead. Bristol Myers Squibb has what it takes to navigate a major patent cliff.
AstraZeneca's (AZN) Truqap Gets EU Nod for Breast Cancer
The European Commission approves AstraZeneca's (AZN) Truqap in combination with Faslodex for ER-positive, HER2-negative advanced or metastatic breast cancer.
AstraZeneca's breast cancer drug combination fails in late-stage trial
AstraZeneca said on Tuesday its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stage trial to improve overall survival of pati...
AstraZeneca Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer
AstraZeneca said its blockbuster cancer drug Imfinzi combined with chemotherapy has been approved by the U.S. as treatment for adult patients with primary, advanced or recurrent endometrial cancer ...
FARXIGA approved in the US for the treatment of pediatric type-2 diabetes
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's FARXIGA® (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycemic control in pediatric patients with type-...
Astrazeneca (AZN) Advances But Underperforms Market: Key Facts
In the closing of the recent trading day, Astrazeneca (AZN) stood at $80.21, denoting a +0.24% change from the preceding trading day.
We're in a difficult business but have the right level of confidence, says AstraZeneca CEO
AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk its lung cancer treatment, late stage drug development, and more.
AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer
AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk its lung cancer treatment, late stage drug development, and more.
Related Companies